Depressive symptoms as a novel risk factor for recurrent venous thromboembolism: a longitudinal observational study in patients referred for thrombophilia investigation. by von Känel, Roland et al.
RESEARCH ARTICLE
Depressive Symptoms as a Novel Risk Factor
for Recurrent Venous Thromboembolism: A
Longitudinal Observational Study in Patients
Referred for Thrombophilia Investigation
Roland von Känel1,2,3*, Angelina Margani2, Stefanie Stauber4, Fiorenza A. Meyer2,
Franziska Demarmels Biasiutti5, Franziska Vökt2, ThomasWissmann2,
Bernhard Lämmle5,6, Paul S. Lukas2,7
1 Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland,
2 Department of Clinical Research, University of Bern, Bern, Switzerland, 3 Department of Psychosomatic
Medicine, Clinic Barmelweid, Barmelweid, Switzerland, 4 Department of Cardiology, Swiss Cardiovascular
Center, Inselspital, Bern University Hospital, and University of Bern, Bern Switzerland, 5 University Clinic of
Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, and University of
Bern, Bern, Switzerland, 6 Center for Thrombosis and Hemostasis, University Medical Center, Mainz,
Germany, 7 Privatklinik für Psychiatrie und Psychotherapie, Sanatorium Kilchberg, Kilchberg, Switzerland
* roland.vonkaenel@insel.ch
Abstract
Background
Increasing evidence suggests that psychosocial factors, including depression predict inci-
dent venous thromboembolism (VTE) against a background of genetic and acquired risk
factors. The role of psychosocial factors for the risk of recurrent VTE has not previously
been examined. We hypothesized that depressive symptoms in patients with prior VTE are
associated with an increased risk of recurrent VTE.
Methods
In this longitudinal observational study, we investigated 271 consecutive patients, aged 18
years or older, referred for thrombophilia investigation with an objectively diagnosed epi-
sode of VTE. Patients completed the depression subscale of the Hospital Anxiety and De-
pression Scale (HADS-D). During the observation period, they were contacted by phone
and information on recurrent VTE, anticoagulation therapy, and thromboprophylaxis in risk
situations was collected.
Results
Clinically relevant depressive symptoms (HADS-D score8) were present in 10% of pa-
tients. During a median observation period of 13 months (range 5-48), 27 (10%) patients ex-
perienced recurrent VTE. After controlling for sociodemographic and clinical factors, a 3-
point increase on the HADS-D score was associated with a 44% greater risk of recurrent
VTE (OR 1.44, 95% CI 1.02, 2.06). Compared to patients with lower levels of depressive
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symptoms (HADS-D score: range 0-2), those with higher levels (HADS-D score: range 3-
16) had a 4.1-times greater risk of recurrent VTE (OR 4.07, 95% CI 1.55, 10.66).
Conclusions
The findings suggest that depressive symptoms might contribute to an increased risk of re-
current VTE independent of other prognostic factors. An increased risk might already be
present at subclinical levels of depressive symptoms.
Introduction
The etiology of incident venous thromboembolism (VTE), comprising deep vein thrombosis
(DVT) of the leg and pulmonary embolism (PE), is multicausal, whereby genetic and acquired
risk factors determine a person’s risk at a specific point in time [1]. Moreover, against a back-
ground risk from acquired prothrombotic conditions and inherited thrombophilia, several fac-
tors might facilitate a prothrombotic milieu resulting in the onset of VTE [2]. For instance,
acute traumatic stress has been implicated as a potential triggering factor of PE [3]. Popula-
tion-based studies revealed psychosocial factors like chronic perceived stress [4], low socioeco-
nomic status (SES) [4–6], and depressive symptoms [7] as predictors of incident VTE,
independent of demographic, life style, and clinical factors [4,5,7]. A plausible explanation for
these links comes from abundant research showing that psychosocial stress, including depres-
sion, evokes hypercoagulability through autonomic and neuroendocrine mechanisms [8].
After a first episode of idiopathic VTE, the risk of another episode is highest in the first year
(i.e., 10–15%) with a cumulative recurrence risk of about 25% at 5 years and 30% at 10 years
[9,10]. Demographic and clinical risk factors of VTE recurrence differ considerably from those
of incident VTE [11]. Unprovoked VTE, proximal DVT and/or PE increase the risk of VTE re-
currence, while extended oral anticoagulation (OAC) therapy lowers the risk [12]. Other im-
portant risk factors for VTE recurrence include higher age, male sex, obesity, high levels of
coagulation factors, and D-dimer levels 250 ng/ml after discontinuing oral OAC therapy
[11–13]. Whether psychosocial factors are associated with an increased risk of VTE recurrence
has not previously been investigated.
Compared with population norms, patients with VTE show impaired physical and mental
quality of life (QoL) [14] and their mental QoL relates to depressive symptoms [15] and is
lower than in patients with other forms of chronic venous diseases [16]. Up to 5 years after PE,
some patients reported PE-related posttraumatic stress symptoms in the form of intrusive
thoughts, flashbacks, and hypervigilance along with depressive symptomatology such as per-
severative cognitions, social withdrawal, and tearfulness [17]. Posttraumatic stress after life-
threatening events other than VTE is associated with depression and elevated clotting factor
VIII activity [18,19], a predictor of VTE recurrence [20]. Likewise, in patients with VTE, nega-
tive emotions, including depression, have been associated with hypercoagulability [21,22]. De-
pression is also associated with poorer OAC management [23], age [24], sex [24], low SES [24],
and obesity [25]. Depressive symptoms thus might be linked with recurrent VTE through de-
mographic and clinical factors, psychological sequelae of VTE, as well as via direct effects
on coagulation.
To the extent that prediction of recurrent VTE remains a clinical challenge [11], the aim of
this study was to shed light on depressive symptoms as a potential and yet unevaluated risk fac-
tor. For this purpose, we assessed depressive symptoms in a cohort of patients with previous
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VTE scheduled for outpatient thrombophilia investigation. We hypothesized that higher levels
of depressive symptoms at thrombophilia investigation would be associated with a greater risk
of future recurrent VTE, whereby taking into account demographic and clinical factors previ-
ously shown to be associated with the risk of VTE recurrence and/or depressive symptoms.
Materials and Methods
Study participants and design
The participants of this longitudinal observational study were 271 consecutive patients who
underwent thrombophilia investigation after an index episode of VTE at the outpatient ward
of the University Clinic of Hematology and Central Hematology Laboratory, Bern University
Hospital, Switzerland, between 03/2006 and 04/2011. For patients who had experienced more
than one episode of VTE prior to referral for thrombophilia investigation, the most recent epi-
sode was defined as the index VTE event. The ethical committee of the State of Bern approved
the study protocol. All participants provided written informed consent. The flowchart of the
271 patients investigated in the present study is shown in Fig 1, whereby the recruitment proce-
dure of the original 2,204 patients scheduled for thrombophilia investigation has previously
been detailed elsewhere [22].
Inclusion criteria for the current study were an objective diagnosis of the index VTE event,
that is DVT of the leg and/or PE, age18 years at thrombophilia investigation, and availability
Fig 1. Flow chart of patient recruitment.
doi:10.1371/journal.pone.0125858.g001
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for follow-up assessment. Objective means to make a diagnosis of the index VTE event were
compression ultrasonography, computed tomography (CT) or magnetic resonance imaging
(MRI) venography, spiral CT, MRI pulmonary angiogram, catheter pulmonary angiography, or
ventilation-perfusion scintigraphy. We included patients with a secondary cause for the index
VTE event if they had a temporary thrombotic risk situation (provoked VTE): oral contraceptive
use [26], pregnancy, surgery, physical trauma, plaster cast, immobilization, dehydration, and
long-distance flight6 hours. Exclusion criteria were persistent risk situations present at the
time of the index VTE event; i.e., cancer, rheumatic diseases, multiple sclerosis [27], inflammato-
ry bowel disease [12], organ transplantation, human immunodeficiency virus infection, and sex
reassignment surgery with hormone replacement. We also excluded patients with a patent fora-
men ovale grade III, as recall of VTE recurrence could be obscured if VTE presents as paradoxi-
cal embolism. Those using antidepressants at thrombophilia investigation were also excluded, as
antidepressant drugs are likely to influence depressive symptoms and hemostasis [28].
A questionnaire for the self-assessment of demographic factors and depressive symptoms
was sent by regular mail to all patients 10 days prior to their clinical visit. Educational attain-
ment was used to define SES (6 patients without graduation were grouped along with those in-
dicating vocational education). Upon arrival at the hematology outpatient clinic, patients
handed in the completed questionnaires. The hematologist obtained a history and asked about
weight and height to compute the body mass index (BMI). Obesity was defined by a BMI30
kg/m2. Additional information regarding the index VTE event, previous episodes of VTE, and
current OAC was abstracted from medical records (note that in Switzerland, OAC at the time
period of this study was almost exclusively established with phenprocoumon). Plasma D-dimer
levels were measured with a quantitative sandwich enzyme immunoassay following the manu-
facturer’s instruction (VIDAS-D-Dimer, bioMérieux, Geneva, Switzerland).
Assessment of depressive symptoms
We assessed symptoms of depression during the previous week with the validated German ver-
sion of the depression subscale of the Hospital Anxiety and Depression scale (HADS-D) [29,
30]. The HADS-D has been widely used for the assessment of depressive symptom severity in
somatic, psychiatric, and primary care patients, as well as in the general population [31]. To
avoid any bias with symptoms from coexisting medical conditions, the HADS-D lacks items re-
ferring to somatic/affective symptoms of depression like sleep and appetite disturbances. The
HADS-D is composed of 7 items each of which is rated on a 4-point Likert scale (0 = not at all,
3 = mostly; total sum score 0–21). Typical items are „I feel as if I am slowed down“; „I still
enjoy the things I used to enjoy”(reverse coding). A score 8 defines the threshold for clinical-
ly relevant symptoms and identifies a major depressive disorder with a sensitivity of 82% and a
specificity of 74% [32]. In the current sample, Cronbach’s alpha was 0.81, indicating good reli-
ability of the HADS-D.
Follow-up assessment
Following the original study protocol, trained and supervised PhD and medical master students
aimed to contact patients by phone for a semi-structured interview twice; that is about 6 months
and 12 months after the clinical visit for thrombophilia investigation, so to minimize the risk of
recall bias. However, for logistical reasons and a shortage in staff resources, the observation pe-
riod had to be extended to achieve two follow-up interviews, whereby 41.3% patients still could
only be reached once. For all the patients, the observation period defined the time interval be-
tween the clinical visit for thrombophilia investigation and the last telephone call. An interview
schedule was used to note patient indications with cross marks during the telephone interview.
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Patients were asked about a new episode of VTE (DVT and/or PE) that had occurred since
the clinical visit for thrombophilia investigation and since the first telephone interview (in
those who had two phone contacts). In the case of a positive answer (yes), we requested hospi-
tal charts with confirmatory imaging test from treating physicians or institutions, whenever
available, to establish a recurrent episode of VTE. Eligible imaging tests included compression
ultrasonography, CT or MRI venography, spiral CT, MRI pulmonary angiogram, catheter pul-
monary angiography, or ventilation-perfusion scintigraphy.
We further asked about anytime use of OAC drugs, compression stockings and/or low
molecular weight heparin in risk situations since the clinical visit for thrombophilia investi-
gation until the telephone interview (in those without VTE recurrence) or occurrence of re-
current VTE.
Data analysis
Data were analyzed with SPSS version 21.0 for Windows (SPSS Inc., Chicago, IL) with signifi-
cance level p<0.05 (2-tailed). We used the expectation maximization algorithm to replace a
few missing HADS-D items (n = 18), and missing data for SES (n = 6), weight (n = 9), height
(n = 6), D-dimer (n = 9), and time from the index VTE event to thrombophilia investigation/
inclusion into the study/completion of the HADS-D subscale, subsequently termed “time since
index VTE” (n = 2). Independent samples t-test with Levene’s test for equality of variances and
chi-square test were used to compare groups with and without recurrent VTE on continuous
and categorical variables, respectively. We calculated Pearson correlation coefficients to esti-
mate the relationship between two variables.
We performed a binary logistic multivariable regression model with recurrent VTE (yes/
no) as the outcome in relation to depressive symptoms as the predicting variable (note that
we did not perform a survival time analysis because the time-to-event could not be verified by
hospital charts in 22.2% of patients who reported a recurrent VTE event during the observa-
tion period). Covariate-adjustment was made for one block of variables with a p<0.20 on bi-
variate analysis associated with recurrent VTE. In a complementary model, we additionally
entered covariates associated with depressive symptoms with a p<0.20 on bivariate analysis,
but separately so to protect the model from being overfitted. We considered the following po-
tentially important covariates based on their known associations with depressive symptoms
and/or risk of recurrent VTE [11–13,21–25,33,34]: age, sex, SES, obesity, recurrent VTE vs.
first-time VTE prior to thrombophilia investigation, proximal DVT and/or PE vs. distal
DVT, unprovoked VTE vs. provoked VTE, D-dimer250 ng/ml vs. <250 ng/ml, OAC at the
time of the clinical visit for thrombophilia investigation (yes/no), as well as any OAC therapy
(yes/no) and thromboprophylaxis in risk situations (yes/no) both since the clinical visit for
thrombophilia investigation.
The primary analysis considered depressive mood as a continuous variable owing to litera-
ture showing that even minimal symptoms of depression, i.e., at subclinical levels, increase
poor prognosis in patients after myocardial infarction [35]. We expressed the relative risk
(odds ratio, OR) with 95% confidence interval (CI) for recurrent VTE in relation to a 3-point
change on the HADS-D scale. This interval is clinically meaningful given the 3-point difference
between the lower bounds of HADS-D scores to define mild (8 points), moderate (11 points),
and severe (14 points) depressive mood [29, 30]. A secondary analysis considered depressive
mood as a categorical variable to test for a potential threshold effect of depressive symptom se-
verity on the risk of recurrent VTE. The Hosmer-Lemeshow test indicated good fit of all mod-
els. Cook’s distance assured the absence of undue outliers.
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Results
Patient characteristics
Table 1 shows the demographic and clinical characteristics of the 271 patients categorized in
two groups based on whether they had experienced a recurrent episode of VTE or not after
thrombophilia investigation. During a median observation period of 13 months (range 5–46),
recurrent VTE was reported by a total of 27 (10.0%) patients and objectively verified by chart
records in 21 cases (no documented imaging tests available in 6 cases).
Unprovoked index VTE was significantly more frequent in patients with recurrent VTE
compared to those without VTE recurrence. The prevalence of clinically relevant depressive
symptoms, as defined by a cut-off on the HADS-D score 8, was 10.0% across the entire sam-
ple and similar in both patient groups. In more detail, depressive mood was mild in 7%, moder-
ate in 2%, and severe in 1% of all patients (in the group with recurrent VTE, mild and
moderate depressive mood were present in one patient each). Yet, there was marginal signifi-
cance for a higher level (mean ±SD) of continuously measured depressive symptoms in pa-
tients with compared to those without recurrent VTE (4.41±2.27 vs. 3.24±3.05, p = 0.058). All
of the other characteristics, assessed at the clinical visit for thrombophilia investigation and
during the observation period, did not significantly differ between the two patient groups.
Associations with depressive symptoms
Depressive symptoms did not significantly associate with characteristics of the index VTE
event, namely first-time VTE vs. recurrent VTE (p = 0.70), proximal DVT and/or PE vs. distal
Table 1. Patient characteristics per recurrence of venous thromboembolism.
Variable Recurrent VTE (n = 27) No recurrent VTE (n = 244) P-value
Index VTE event
First-time VTE, n (%) 18 (66.7%) 184 (75.4) 0.322
Proximal DVT and/or PE, n (%) 17 (63.0) 160 (65.6) 0.787
Unprovoked VTE, n (%) 21 (77.8) 130 (53.3) 0.015
Time since index VTE (months) 8 (5–14) 8 (5–12) 0.615
Age (years) 47 (43–62) 47 (36–59) 0.084
Male sex, n (%) 18 (66.7) 128 (52.5) 0.160
Educational level, n (%)
Graduate school (university) 16 (59.3) 95 (39.0) 0.119
Tertiary education 8 (29.6) 116 (47.5)
Vocational education 3 (11.1) 33 (13.5)
Body mass index (kg/m2) 26.9 (25.1–30.7) 26.4 (23.9–28.8) 0.204
Obesity, n (%) 7 (25.9) 50 (20.5) 0.511
D-dimer 250 ng/ml, n (%) 17 (63.0) 149 (61.1) 0.848
Current OAC therapy, n (%) 7 (25.9) 64 (26.2) 0.973
Depressive symptoms (score) 4 (3–6) 2 (1–5) 0.058
Clinically depressed, n (%) 2 (7.4) 25 (10.2) 1.000
Observation period
Duration (months) 13 (12–27) 13 (12–24) 0.615
2 phone calls, n (%) 16 (59.3) 143 (58.6) 0.948
OAC therapy, n (%) 6 (22.2) 76 (31.1) 0.3838
Thromboprophylaxis, n (%) 22 (81.5%) 174 (71.3) 0.262
OAC, oral anticoagulation; DVT, deep venous thrombosis; PE, pulmonary embolism; VTE, venous thromboembolism. Data are given as number of
observations (n) and percentage of total (%) or median with interquartile range. P-values refer to group comparison.
doi:10.1371/journal.pone.0125858.t001
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DVT (p = 0.29), unprovoked VTE vs. provoked VTE (p = 0.98), and time since index VTE
(p = 0.86).
In terms of demographic and clinical factors, depressive symptoms showed no significant
relationship with SES (r = -0.12, p = 0.051), age (p = 0.32) and sex (p = 0.55). More depressive
symptoms were significantly associated with obesity (r = 0.13, p = 0.040), but not with elevated
D-dimer (p = 0.93), even when controlling for current OAC use (p = 0.67).
Regarding the observation period, depressive symptoms were significantly associated with
greater use of OAC (r = 0.14, p = 0.026), but not with the duration of the observation period (r =
0.11, p = 0.074), the number of phone contacts (p = 0.50), and thromboprophylaxis (p = 0.99).
Association of depressive symptoms with VTE recurrence in the
multivariable analysis
In the aforementioned analyses, age, sex, SES, and unprovoked VTE were revealed as correlates
of recurrent VTE with a significance level of p<0.20 and thus considered as covariates in the
multivariable model. Table 2 shows the covariate-adjusted logistic regression model for the re-
lation of depressive symptoms with the risk of VTE recurrence during the observation period.
For a three-point increase in the level of depressive symptoms, there was a 44% increase in the
relative risk of recurrent VTE, whereas sociodemographic factors and unprovoked VTE were
not significantly predictive in their own right.
Because only two patients with recurrent VTE scored8 on the HADS-D scale, there was
limited power to test for a predictive value of this categorical measure of clinically relevant de-
pressive symptoms for the risk of VTE recurrence. Therefore, we performed a median split on
HADS-D scores yielding two groups of patients with relatively higher (5.52±2.73, range 3–16;
n = 141) vs. relatively lower (1.01±0.75, range 0–2; n = 130) levels of depressive symptoms.
After adjustment for age, sex, SES, and unprovoked VTE, the relative risk of developing recur-
rent VTE was 4.1-times higher in patients with higher compared to those with lower levels of
depressive symptoms (OR 4.069, 95% CI 1.553, 10.664; p = 0.004).
In three complementary models, we adjusted for variables which associated with depressive
symptoms in the correlation analysis with a significance level of p<0.20 in addition to age, sex,
SES, and unprovoked VTE. After additional adjustment for obesity, OAC use during the obser-
vation period, and duration of the observation period, a 3-point increase in depressive symp-
toms remained a significant predictor of recurrent VTE, whereby increasing the relative risk by
44%, 57%, and 44%, respectively. The significance of results of the categorical analysis was also
maintained with these adjustments (data not shown).
We also performed a sensitivity analysis with adjustment for age, sex, SES, and unprovoked
VTE, for which we excluded the 6 patients who could not be objectively diagnosed with respect
Table 2. Risk of recurrence of venous thromboembolismwith depressive symptoms.
Entered variables Odds ratio 95% CI P-value
Age 1.019 0.986, 1.053 0.273
Male sex 1.088 0.433, 2.735 0.858
Educational level 1.740 0.907, 3.338 0.096
Unprovoked venous thromboembolism 2.478 0.899, 6.829 0.079
Depressive symptoms 1.444 1.015, 2.056 0.041
Depressive symptoms were entered in steps of 3 points. The model accounted for 10.5% of the variance
(chi square = 13.99, df = 5, p = 0.016).
doi:10.1371/journal.pone.0125858.t002
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to recurrent VTE. For a three-point increase in the level of depressive symptoms, there was a
30% increase in the relative risk of recurrent VTE (OR 1.290, 95% CI 0.855, 1.946; p = 0.23).
Moreover, the relative risk of developing recurrent VTE was 3.6-times higher in patients with
more (range of HADS-D score: 3–16) than in those with less (range of HADS-D score 0–2) de-
pressive symptoms (OR 3.629, 95% CI 1.267, 10.396; p = 0.016).
Discussion
We found that depressive symptoms were significantly predictive for an increased risk of recur-
rent VTE in patients with a prior episode of VTE during a median observation period of about
one year. This relationship was independent of demographic and clinical variables, which have
also previously been shown to be associated with depression and/or the risk of recurrent VTE,
and thus could have accounted for at least some of the increased risk of VTE recurrence with
depressive mood. Expectedly, an episode of unprovoked index VTE was more frequent in pa-
tients with recurrent VTE than in those without VTE recurrence [12], while depressive symp-
toms showed the known association with obesity [25]. However, none of the covariates was
revealed as an independent predictor of recurrent VTE above and beyond depressive symp-
toms in the multivariable model.
To our knowledge, our study is the first to show that a psychosocial factor is significantly as-
sociated with an increased risk of future recurrent VTE. Population-based studies have shown
that psychosocial factors, including depressive symptoms, are prospectively related with inci-
dent VTE [4–7]. A parallel line of research on the etiology and prognosis of atherothrombotic
diseases demonstrates that depressive symptoms are important for both incident and recurrent
events [36, 37], even after controlling for sociodemographic variables, cardiac disease severity,
and traditional cardiovascular risk factors [38]. The worldwide INTERHEART case-control
study reported that perceived stress (due to work, home, finances or life events), and depression
accounted for approximately one third of the population attributable risk of acute myocardial
infarction [39]. Therefore, it is intriguing to assume that psychosocial variables, like depression,
might as well account for a relevant portion of the risk of incident and recurrent VTE.
In our study, a 3-point higher level in depressive symptoms was associated with a 44% higher
relative risk of VTE recurrence. In clinical terms, a patient with severe depressive mood, based
on a HADS-D score of 14, would have an almost 1.5-fold higher risk of recurrent VTE than a
patient with moderate depressive mood (HADS-D score of 11) and an almost 2-fold higher risk
than a patient with mild depressive mood (HADS-D score of 8). We acknowledge that such im-
plications are not beyond dispute, particularly regarding the risk inferred for more severely de-
pressed patients. We found that only 10.0% of our patients scored in the range of clinically
relevant depressive symptoms, whereby 7% had mild depressive mood and 3% had moderate or
severe depressive mood. Nonetheless, the prevalence of a HADS-D score8 in our study par-
ticipants quite compares with the previously reported 15.5% of patients hospitalized with acute
myocardial infarction meeting this cut-off [40]. And this even more so, as our patients were on
average in a comparably less acute phase of the disease with studies showing, mental health is
less impaired with longer time elapsed since the last VTE episode [41, 42]. Clearly, whether our
findings are applicable to psychiatric patients and those with more severe depression remains to
be seen. A retrospective study found a diagnosis of depression to be more frequent in psychiat-
ric patients aged 65 or older who developed VTE during hospitalization than in those who did
not, yet, only 5 out of 192 patients developed VTE in that study [43].
Because our study did not have the power to statistically test for an effect of clinically rele-
vant depressive symptoms on the risk of VTE recurrence, we categorized HADS-D scores per
cut-off in subclinical range of depressive mood. We found that levels of depressive symptoms
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not generally considered to be clinically relevant were associated with an increased risk of re-
current VTE. Specifically, independent of covariates, the group of patients scoring with at least
3 points on the HADS-D scale had an approximately 4-fold higher risk of future recurrent
VTE relative to the group with a score of 2 or fewer points. The selection of this cut-off can be
deemed arbitrary as it depends of the distribution of depressive symptoms in a given study
sample. Nevertheless, the finding concurs with studies in patients with myocardial infarction
showing that even minimal symptoms of depression significantly worsen the prognosis of the
cardiac disease [35, 44].
We are not aware of any depression treatment studies in patients with VTE. However, the
identification of potentially important psychosocial factors provides the possibility to intervene
with mental health treatments to improve QoL [15] via alleviating depressive mood and perhaps
even the risk of VTE recurrence. Counseling that includes advice from healthcare professionals
on coping with problems (e.g., the fact of having experienced VTE) might be sufficient for the
treatment of mild depression; moderately severe depression is generally responsive to psycho-
therapy, a physical exercise program, and/or antidepressants [45]. Regarding the latter, clinicians
should be aware that SSRIs (e.g. paroxetine, fluoxetine) and SNRIs (e.g., venlafaxine, duloxetine)
increase the risk of bleeding through interacting with OAC and platelet function [46]. In con-
trast, hypericum perforatum (St. John's wort) lowers plasma concentration of OAC drugs [47].
Moreover, tricyclics and antidepressants blocking serotonin receptors or with low potency of se-
rotonin reuptake inhibition have been associated with an increased risk of VTE [48].
We mention several limitations of our study. We accounted for low SES that is associated
with depression [24] and a wide range of poor healthcare outcomes [49], as well as for throm-
boprophylaxis and OAC during the observation period. However, depressive patients previous-
ly showed reduced OAC control [23] and compliance with medical treatment
recommendations [50]. More objective measures, like percent time in the therapeutic range to
monitor quality of OAC, should be considered in future studies. This would allow to test
whether the impact of depressive symptoms on recurrent VTE is independent of poor OAC
control or causally mediated through this mechanism. Inherent to observational studies, there
remains a possibility of residual confounding through unrecognized and unassessed influenc-
ing factors. We cannot exclude a misclassification bias for our outcome variable. Depressive pa-
tients perceive their health as poorer than non-depressed ones [51]. Therefore, a recall bias
regarding self-reports of VTE recurrence must be considered; this is of particular concern re-
garding the impossibility to objectify patient reports on VTE recurrence in 22.2% of cases. In
fact, the relation between continuously (but not categorically) scaled depressive symptoms and
the risk of VTE recurrence was attenuated to nonsignificance in a sensitivity analysis, for
which these cases were excluded; however, this interpretation must consider reduced statistical
power compared with the primary analysis.
Insufficient statistical power precluded stratified analyses in subgroups based on character-
istics of the index VTE. For instance, the risk of future recurrent VTE may differ between sub-
jects with one previous VTE event from those with several previous VTE events. Depressive
patients tend to be more sedentary but we did not assess physical activity as a control variable
that might account for some of the VTE risk. The results from this study might not generalize
to psychiatric patients and geriatric populations with high comorbidity. We only studied pa-
tients who could be reached by phone, so we had no information available on the number of
patients who died and the cause of death, including recurrent VTE. The exact duration of OAC
therapy and number of patients on long-term OAC therapy could not reliably be verified from
hospital charts, so we considered current use of OAC at study entry and anytime use of OAC
during the observation period as potential covariates.
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Conclusions
We found that even subclinical levels of depressive symptoms after an index episode of VTE
are significantly associated with the risk of recurrent VTE during a median observation period
of about one year. In spite of its limitations, our study is of clinical interest and hypothesis-gen-
erating, as it is the first to suggest psychosocial factors may be important for VTE recurrence,
so larger follow-up studies may be warranted. Also, the biobehavioral mechanisms linking de-
pression, and perhaps other psychosocial factors with VTE recurrence, await
further investigations.
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